Subjects: ENVELHECIMENTO, IDOSOS, DIABETES MELLITUS, NEFROPATIAS, MÉTODO DUPLO-CEGO, RESULTADO DE TRATAMENTO
ABNT
HEERSPINK, Hiddo J. L et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, v. 393, n. 10184, p. 1937-1947, 2019Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(19)30772-X. Acesso em: 30 ago. 2024.APA
Heerspink, H. J. L., Parving, H. -H., Andress, D. L., Bakris, G., Correa-Rotter, R., Hou, F. -F., et al. (2019). Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, 393( 10184), 1937-1947. doi:10.1016/S0140-6736(19)30772-XNLM
Heerspink HJL, Parving H-H, Andress DL, Bakris G, Correa-Rotter R, Hou F-F, Kitzman DW, Kohan D, Makino H, Burdmann E de A. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial [Internet]. Lancet. 2019 ; 393( 10184): 1937-1947.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(19)30772-XVancouver
Heerspink HJL, Parving H-H, Andress DL, Bakris G, Correa-Rotter R, Hou F-F, Kitzman DW, Kohan D, Makino H, Burdmann E de A. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial [Internet]. Lancet. 2019 ; 393( 10184): 1937-1947.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(19)30772-X